Michael Wood, MD
Interventional Cardiology · Washington, MONPI 1508995150
Payments from drug & device makers
Across 423 payments — averaging $33.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Ultragenyx Pharmaceutical Inc.$7K
- Medtronic$2K
- Novartis$807
- Boehringer Ingelheim$664
- Johnson & Johnson$661
- Abbott$611
- plus $3K from 31 others
What the payments were for
- Consulting fees$6,70547%
- Food & beverage$7,59053%
- Education$70%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Ultragenyx Pharmaceutical Inc. | 6 | $6,675 |
| Medtronic(2 entities) | 77 | $1,541 |
| Novartis | 48 | $807 |
| Boehringer Ingelheim | 41 | $664 |
| Johnson & Johnson | 49 | $661 |
| Abbott | 32 | $611 |
| Pfizer | 24 | $450 |
| AstraZeneca | 22 | $339 |
| Amgen | 19 | $289 |
| W. L. Gore & Associates, Inc. | 7 | $255 |
| Angiodynamics, Inc. | 12 | $250 |
| Shockwave Medical, Inc | 10 | $240 |
| Boston Scientific | 10 | $206 |
| E.r. Squibb & Sons, L.L.C. | 11 | $189 |
| Novo Nordisk | 11 | $187 |
| Abiomed | 4 | $125 |
| Edwards Lifesciences | 2 | $107 |
| Cardiovascular Systems Inc. | 6 | $88 |
| Cvrx, Inc. | 4 | $79 |
| Surmodics, Inc. | 4 | $73 |
| Lilly USA, LLC | 3 | $53 |
| Lemaitre Vascular, Inc. | 1 | $47 |
| Regeneron Healthcare Solutions, Inc. | 3 | $46 |
| Penumbra, Inc. | 1 | $46 |
| Terumo Medical Corporation | 3 | $44 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $27 |
| Irhythm Technologies, Inc. | 1 | $26 |
| Actelion Pharmaceuticals US, Inc. | 1 | $26 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $23 |
| Bayer | 1 | $21 |
| Sanofi-aventis U.S. LLC | 1 | $20 |
| Esperion Therapeutics, Inc. | 1 | $18 |
| Merck | 1 | $16 |
| Getinge USA Sales, LLC | 1 | $14 |
| Inari Medical, Inc. | 1 | $14 |
| Bard Peripheral Vascular, Inc. | 1 | $13 |
| Amarin Pharma, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- RESOLUTE ONYX$152
- LINQ II$123
- Micra$108
How this compares
$14,302 in reported general payments places this provider in the 50th percentile of 182 interventional cardiology providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 296 | $253,438 |
| XareltoRivaroxaban | 155 | $139,052 |
| EntrestoSacubitril/Valsartan | 68 | $56,890 |
| Repatha SureclickEvolocumab | 65 | $51,887 |
| BrilintaTicagrelor | 31 | $19,492 |
| Repatha SyringeEvolocumab | 18 | $9,948 |
| Praluent PenAlirocumab | 15 | $7,757 |
| FarxigaDapagliflozin Propanediol | 11 | $6,240 |
| Flecainide Acetate | 66 | $3,025 |
| Atorvastatin Calcium | 294 | $2,967 |
| Bumetanide | 56 | $2,562 |
| Metoprolol Succinate | 209 | $2,286 |
| Clonidine | 13 | $2,079 |
| Mexiletine Hcl | 19 | $1,950 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 76 | $1,871 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $450 | $253,438296 claims |
| Johnson & JohnsonXarelto | $661 | $139,052155 claims |
| NovartisEntresto | $807 | $56,89068 claims |
| AstraZenecaBrilinta, Farxiga | $339 | $25,73342 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 182 interventional cardiology providers in Missouri.
Other interventional cardiology in Washington
- Joshua StolkerWashington$1.2M
- Roberto Pacheco CoronadoWashington$367K
- Stephen KuehnWashington$57K
- Harvey SerotaSaint Louis$7.1M
- Adnan ChhatriwallaKansas City$3.6M
- Gil VardiSaint Louis$2M
- Alan ZajariasSaint Louis$1.6M
- James GranthamKansas City$1.6M
- Anish ThomasSaint Louis$1.5M
- Richard BachSaint Louis$1.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.